CLINICAL TRIALS PROFILE FOR TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE
✉ Email this page to a colleague
505(b)(2) Clinical Trials for tipiracil hydrochloride; trifluridine
| Trial Type | Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|---|
| New Combination | NCT07235293 ↗ | A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer. | NOT_YET_RECRUITING | Novotech (Australia) Pty Limited | PHASE2 | 2025-11-15 | This clinical study is testing whether a new combination of medicines (DSP107 and atezolizumab) is more effective and safer than an existing treatment (fruquintinib) for people with advanced colorectal cancer that is microsatellite stable (MSS). Participants will be randomly assigned to receive one of the two treatments, and researchers will monitor how well the cancer responds, how safe the treatments are, and how the body processes them. The study hopes to show that the new combination can improve outcomes for patients with this type of colorectal cancer. |
| New Combination | NCT07235293 ↗ | A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer. | NOT_YET_RECRUITING | Kahr Bio Australia Pty Ltd | PHASE2 | 2025-11-15 | This clinical study is testing whether a new combination of medicines (DSP107 and atezolizumab) is more effective and safer than an existing treatment (fruquintinib) for people with advanced colorectal cancer that is microsatellite stable (MSS). Participants will be randomly assigned to receive one of the two treatments, and researchers will monitor how well the cancer responds, how safe the treatments are, and how the body processes them. The study hopes to show that the new combination can improve outcomes for patients with this type of colorectal cancer. |
| >Trial Type | >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
All Clinical Trials for tipiracil hydrochloride; trifluridine
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01955837 ↗ | Study of Trifluridine/Tipiracil (TAS-102) in Patients With Metastatic Colorectal Cancer in Asia | Completed | Taiho Pharmaceutical Co., Ltd. | Phase 3 | 2013-09-01 | To compare the effects of TAS-102 with placebo in patients with metastatic colorectal cancer refractory or intolerable to standard chemotherapies. |
| NCT02654639 ↗ | Ph 2 Study of TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal Cancer | Terminated | Georgetown University | Phase 2 | 2016-02-01 | Phase II study of TAS-102 plus bevacizumab switch maintenance therapy in patients with mCRC |
| NCT03278106 ↗ | TAS-102 in Treating Advanced Biliary Tract Cancers | Active, not recruiting | National Cancer Institute (NCI) | Phase 2 | 2017-10-20 | This phase II trial studies how well trifluridine/tipiracil hydrochloride combination agent TAS-102 (TAS-102) works in treating participants with biliary tract cancers that have spread to other places in the body. Drugs used in the chemotherapy, such as trifluridine/tipiracil hydrochloride combination agent TAS-102, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. |
| NCT03278106 ↗ | TAS-102 in Treating Advanced Biliary Tract Cancers | Active, not recruiting | Mayo Clinic | Phase 2 | 2017-10-20 | This phase II trial studies how well trifluridine/tipiracil hydrochloride combination agent TAS-102 (TAS-102) works in treating participants with biliary tract cancers that have spread to other places in the body. Drugs used in the chemotherapy, such as trifluridine/tipiracil hydrochloride combination agent TAS-102, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for tipiracil hydrochloride; trifluridine
Condition Name
| Condition Name for tipiracil hydrochloride; trifluridine | |
| Intervention | Trials |
| Metastatic Colorectal Cancer | 22 |
| Colorectal Cancer | 9 |
| Stage IV Colorectal Cancer AJCC v8 | 7 |
| Stage IVB Colorectal Cancer AJCC v8 | 6 |
| [disabled in preview] | 1 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
Clinical Trial Locations for tipiracil hydrochloride; trifluridine
Trials by Country
Clinical Trial Progress for tipiracil hydrochloride; trifluridine
Clinical Trial Phase
Clinical Trial Sponsors for tipiracil hydrochloride; trifluridine
Sponsor Name
